Methods of treating and preventing gout and lead nephropathy

A toxicity and gout technology, applied in the fields of antidote, bone disease, pharmaceutical formula, etc., can solve the problems of drug hypersensitivity, exacerbation of acute gout attacks, difficulty in taking dosage, etc.

Inactive Publication Date: 2018-01-12
CANTRUST LIFESCI CORP
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, whether allopurinol actually exacerbates acute gout attacks in the first place remains controversial
Allopurinol also has two disadvantages: first, it can be difficult to dose; second, some patients are

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating and preventing gout and lead nephropathy
  • Methods of treating and preventing gout and lead nephropathy
  • Methods of treating and preventing gout and lead nephropathy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0073] Example 1 - CT°I induces a decrease in serum urate

[0074] CT°I is directly involved in the neutralization of free radicals and reactive oxygen species. The effect of CT°I on serum urate includes at least two possible aspects: 1) through the interaction with xanthine oxidase to directly reduce urate production; 2) through the reduction of renal function induced by CT°I Improvement indirectly reduces serum urate levels.

[0075] Such as figure 1 As shown, the average serum urate of the subjects tested was 521.07±40.11 mg / L at their first visit and 346.46±21.17 mg / L after 12 weeks of treatment. This represents a 33.51% decrease in serum urate. The decrease in serum urate after 8 weeks of treatment was significantly different (p<0.05).

example 2

[0076] Example 2 - CT°I Induces Improvement of Renal Function

[0077] All subjects were classified as renally impaired (glomerular filtration rate <80 ml / min). The serum creatinine test measures the level of creatinine in the blood and provides an estimate of the glomerular filtration rate, which indicates the excretory function of the kidneys. If the kidneys are not functioning properly, elevated creatinine levels may build up in the blood.

[0078] Such as figure 2 As shown, the mean serum creatinine of the subjects tested was 135.29±6.89 μmol / L at their first visit and 99.00±4.45 μmol / L after 12 weeks of treatment. This represents a 26.82% decrease in serum creatinine. The decrease in serum creatinine after 8 weeks of treatment was significantly different (p<0.05).

example 3

[0079] Example 3 - CT°I induces a decrease in blood lead levels

[0080] Lead is toxic to the kidneys. Accumulated heavy metal ions, including lead, damage the body primarily through their intense oxidative damage to major organs, especially the kidneys and liver. CT°I protects the body from heavy metal ion poisoning mainly through its direct chelation and its enhanced antioxidant effect.

[0081] Such as image 3 As shown, the average blood lead level of the subjects tested was 49.90±8.41 μg / dL at their first visit and 37.26±6.29 μg / dL after 12 weeks of treatment. This represents a 25.33% drop in blood lead levels. The reduction in blood lead levels after 12 weeks of treatment was significantly different (p<0.05).

[0082] other embodiments

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed here is a novel use of a pharmaceutical composition comprising glutathione or its pharmaceutically acceptable salts or derivatives as active ingredient, in the forms of tablets, capsules, powder, spray and/or liquid, through oral administration, intervene injection, inhale and/or skin transmission, to treat and prevent gout and lead nephropathy. Embodiments of gout and lead nephropathy treatable by the pharmaceutical composition described herein include, without limitation, gout, kidney stones, tophi, hyperuricemia, blood lead, renal disease (lead nephropathy), complications thereof,as well as other conditions caused by lifestyle, genetics, medical conditions, and blood lead level. Symptoms treatable may include inflammatory arthritis, which typically involves a red, tender, hot, and swollen joint.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 62 / 358,306, filed July 5, 2016, which is hereby incorporated by reference in its entirety. Background technique [0003] Gout is a metabolic syndrome caused by the deposition of uric acid crystals in body tissues and fluids. This process is caused by overproduction and / or underexcretion of uric acid. Certain commonly used drugs, lead, alcohol, and dietary foods are thought to be contributing factors. Acute gout usually presents as an acute attack of red, hot, swollen, and excruciating pain in the joints. Oral anti-inflammatory drugs are effective in the symptomatic treatment of acute gout attacks, and drug therapy and changing dietary habits can prevent gout attacks. Recurrent episodes of acute gout can lead to degenerative chronic arthritis, known as gouty arthritis. [0004] Gout can lead to inflammatory arthritis, the most common form of inflammato...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/06A61P19/06A61P39/02A61P13/12A61P19/02A61P29/00A61P13/04
CPCA61K9/0053A61K38/063A61P13/04A61P13/12A61P19/02A61P19/06A61P29/00A61P39/02
Inventor 格雷斯·乔张丽丽乔峰戴龙君
Owner CANTRUST LIFESCI CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap